



SM-88 efficacy across multiple high-risk factors.

Authors:

Xinhua Zhu, Marcus Smith Noel, Patricia Zawisny, Zachary Gostout, Douglas Decorato, Maria Loushin, Giuseppe Del Priore; Monter Cancer Center of North Shore - LIJ Health, Lake Success, NY; University of Rochester James P. Wilmot Cancer Institute, Strong Memorial Hospital, Rochester, NY; QRI, New York, NY; Tyme Technologies, Inc., New York, NY; East River Medical Imaging, NY, NY; Quality Research and Invention LLC, New York, NY; Morehouse School of Medicine, Atlanta, GA

Background:

SM-88 is a relatively non-toxic novel combination therapy of dysfunctional tyrosine, CYP3a4 inducer, mTOR inhibitor and oxidative stress catalyst. Early testing with over 100 subjects has shown potential efficacy in 13 different cancer types (JCO 2013, e2209) with manageable toxicity (no grade 3-5 drug-related AEs). We now report tumor agnostic activity across multiple high-risk factors.

Methods:

Retrospective chart review of subjects treated with SM-88 (aka SMK) under Phase I or compassionate use. All subjects received SM-88 5 days/week.

Results:

83 evaluable subjects were identified from 107 subjects treated with SM-88 between 2012–7. Mean age was 53 (7 – 82); 95% white; median prior systemic therapies: 1 (0 – 8), and baseline ECOG: 1 (0 – 4). At diagnosis: 7% Stage I, 13% Stage II, 14% Stage III, 37% Stage IV, and 28% unknown. At time of SM-88 treatment: 47% refractory, 33% recurrent, 2% stable, and 18% unknown. Primaries included: 30% breast, 12% pancreatic, 10% lung, and 6% prostate. Overall RR (CR+PR) was 41% (34/83); 14% (12/83) were CRs, 27% PRs, 40% SD, with 19% PD or unknown. Median PFS by response was CR - 16 months, PR - 12 mo, SD - 8 mo, and PD/UNK - 0 months. Median OS by response was 49, 14, 17, and 4 months, respectively. Responses were seen in 11/25 breast (44%), 3/10 pancreas (30%), 1/8 of lung (13%), and 3/5 of prostate (60%). Other outcomes included overall improvement of ECOG PS in 55% and 47% of

EORTC QLQ-C30 “overall health” and “overall quality of life” plus pain reduction (NRS-11) in 40%. Responses were not affected by typical high risk factors (see table, * X2p<0.05).

Conclusions:

SM-88 has demonstrated potential efficacy in various cancer types with a favorable safety and QOL profile. There was no indication of cross-resistance based on prior treatments, metastatic site or other poor prognosis indicators.

Low Risk Factor	ORR	Median PFS mo	High Risk Factor	ORR	Median PFS mo
1L Prior Systemic n=28	43%	13	>1L Prior Systemic (median 3, 2-8) n=24	42%	4
Visceral Disease Only n=39	26%	7	Visceral & Bone Metastases n=17	41%	4
ECOG PS <= 1 n=36	39%	10	ECOG PS >1 n=30	47%	6
Duration > 6 mo. n=23	74%*	16	Therapy Duration 2-6 mo. n=60	28%	4
Weight < BMI 30 n=52	44%	9	Weight > BMI 30 n=8	50%	14
Monotherapy n=58	43%	13	Combination Therapy n=23	39%	5

